Modeling Tissue Specific Plasma Membranes in Silico
نویسندگان
چکیده
منابع مشابه
Thromboplastin (tissue factor) in plasma membranes of human monocytes.
The synthesis of thromboplastin, a potent trigger of blood coagulation, can be induced in human peripheral blood monocytes. Indirect evidence suggests that newly synthesized thromboplastin becomes in part available on the cell surface. We have attempted to study the localization and availability of thromboplastin more directly by isolating plasma membranes from isolated human peripheral blood m...
متن کاملIn silico design of robust bolalipid membranes.
The robustness of microorganisms used in industrial fermentations is essential for the efficiency and yield of the production process. A viable tool to increase the robustness is through engineering of the cell membrane and especially by incorporating lipids from species that survive under harsh conditions. Bolalipids are tetraether lipids found in Archaea bacteria, conferring stability to thes...
متن کاملSpecific binding of calcitonin to rat liver plasma membranes.
The binding of human calcitonin (CT) was investigated in the plasma membrane fraction obtained from normal rat liver. The liver plasma membrane bound 125I-labeled [( 125I]) human CT, with increasing concentrations of the plasma membrane protein from 4.6-80 micrograms/ml, in a both time and temperature dependent manner. Specific binding of [125I] human CT was competitively inhibited by concentra...
متن کاملSpecific recognition of plasma membranes by embryonic cells.
Methods have been developed for preparation of plasma membrane fractions from embryonic neural retina and cerebellum. These membrane fractions are specifically bound by intact cells of the original tissue (homotypic binding) and not by cells from the other tissue (heterotypic binding). Aggregation of neural retina cells and cerebellar cells is prevented by addition of homotypic membranes but no...
متن کاملOfatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling
Background: Ofatumumab, an anti-CD20 mAb, was approved in 2009 for the treatment of chronic lymphocytic leukemia. This mAb acts through immune-mediated mechanisms, in particular complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by natural killer cells as well as antibody-dependent phagocytosis by macrophages. Apoptosis induction is another mechanism of this antibody...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biophysical Journal
سال: 2017
ISSN: 0006-3495
DOI: 10.1016/j.bpj.2016.11.2042